Aarkstore - Pruritus - Pipeline Review, H2 2014

1
Pruritus - Pipeline Review, H2 2014
Pharmaceutical and Healthcare Market Research
Report
2
Summary

• Pruritus - Pipeline Review, H2 2014, provides an
  overview of the Prurituss therapeutic pipeline.
• This report provides comprehensive information
  on the therapeutic development for Pruritus,
  complete with comparative analysis at various
  stages, therapeutics assessment by drug target,
  mechanism of action (MoA), route of
  administration (RoA) and molecule type, along
  with latest updates, and featured news and press
  releases. It also reviews key players involved in
  the therapeutic development for Pruritus and
  special features on late-stage and discontinued
  projects.
• Global Markets Directs report features
  investigational drugs from across globe covering
  over 20 therapy areas and nearly 3,000
  indications. The report is built using data and
  information sourced from Global Markets Directs
  proprietary databases, Company/University
  websites, SEC filings, investor presentations and
  featured press releases from company/university
  sites and industry-specific third party sources,
  put together by Global Markets Directs team. Drug
  profiles/records featured in the report undergoes
  periodic updation following a stringent set of
  processes that ensures that all the profiles are
  updated with the latest set of information.

3
Scope

• - The report provides a snapshot of the global
  therapeutic landscape of Pruritus- The report
  reviews key pipeline products under drug profile
  section which includes, product description, MoA
  and RD brief, licensing and collaboration
  details other developmental activities - The
  report reviews key players involved in the
  therapeutics development for Pruritus and enlists
  all their major and minor projects- The report
  summarizes all the dormant and discontinued
  pipeline projects - A review of the Pruritus
  products under development by companies and
  universities/research institutes based on
  information derived from company and
  industry-specific sources- Pipeline products
  coverage based on various stages of development
  ranging from pre-registration till discovery and
  undisclosed stages- A detailed assessment of
  monotherapy and combination therapy pipeline
  projects- Coverage of the Pruritus pipeline on
  the basis of target, MoA, route of administration
  and molecule type- Latest news and deals
  relating related to pipeline products

4
Reasons to buy

• - Provides strategically significant competitor
  information, analysis, and insights to formulate
  effective RD development strategies- Identify
  emerging players with potentially strong product
  portfolio and create effective counter-strategies
  to gain competitive advantage- Develop strategic
  initiatives by understanding the focus areas of
  leading companies- Identify and understand
  important and diverse types of therapeutics under
  development for Pruritus- Plan mergers and
  acquisitions effectively by identifying key
  players of the most promising pipeline- Devise
  corrective measures for pipeline projects by
  understanding Pruritus pipeline depth and focus
  of Indication therapeutics- Develop and design
  in-licensing and out-licensing strategies by
  identifying prospective partners with the most
  attractive projects to enhance and expand
  business potential and Scope- Modify the
  therapeutic portfolio by identifying discontinued
  projects and understanding the factors that drove
  them from pipeline

5
Table of Content

• IntroductionREPORT COVERAGEPruritus
  OverviewTherapeutics DevelopmentPipeline
  Products for Pruritus - OverviewPipeline
  Products for Pruritus - Comparative
  AnalysisPruritus - Therapeutics under
  Development by CompaniesPruritus - Therapeutics
  under Investigation by Universities/InstitutesPru
  ritus - Pipeline Products GlanceLate Stage
  ProductsClinical Stage ProductsEarly Stage
  ProductsPruritus - Products under Development by
  CompaniesPruritus - Products under Investigation
  by Universities/InstitutesPruritus - Companies
  Involved in Therapeutics DevelopmentJohnson
  JohnsonShionogi Co., Ltd.GlaxoSmithKline plc

6
List of Tables

• Number of Products under Development for
  Pruritus, H2 2014Number of Products under
  Development for Pruritus - Comparative Analysis,
  H2 2014Number of Products under Development by
  Companies, H2 2014Number of Products under
  Investigation by Universities/Institutes, H2
  2014Comparative Analysis by Late Stage
  Development, H2 2014Comparative Analysis by
  Clinical Stage Development, H2 2014Comparative
  Analysis by Early Stage Development, H2
  2014Products under Development by Companies, H2
  2014Products under Investigation by
  Universities/Institutes, H2 2014Pruritus -
  Pipeline by Johnson Johnson, H2 2014Pruritus -
  Pipeline by Shionogi Co., Ltd., H2
  2014Pruritus - Pipeline by GlaxoSmithKline plc,
  H2 2014Pruritus - Pipeline by Merck Co., Inc.,
  H2 2014Pruritus - Pipeline by Santen
  Pharmaceutical Co., Ltd., H2 2014Pruritus -
  Pipeline by Amorepacific Corporation, H2
  2014Pruritus - Pipeline by LEO Pharma A/S, H2
  2014Pruritus - Pipeline by Nippon Shinyaku Co.,
  Ltd., H2 2014

7
List of Figures

• Number of Products under Development for
  Pruritus, H2 2014Number of Products under
  Development for Pruritus - Comparative Analysis,
  H2 2014Number of Products under Development by
  Companies, H2 2014Comparative Analysis by
  Clinical Stage Development, H2 2014Comparative
  Analysis by Early Stage Products, H2
  2014Assessment by Monotherapy Products, H2
  2014Number of Products by Top 10 Target, H2
  2014Number of Products by Stage and Top 10
  Target, H2 2014Number of Products by Top 10
  Mechanism of Action, H2 2014Number of Products
  by Stage and Top 10 Mechanism of Action, H2
  2014Number of Products by Top 10 Route of
  Administration, H2 2014Number of Products by
  Stage and Top 10 Route of Administration, H2
  2014Number of Products by Top 10 Molecule Type,
  H2 2014Number of Products by Stage and Top 10
  Molecule Type, H2 2014

8
Related Reports

• Fabry Disease-Pipeline Insights, 2015
• Ocular Hypertension-Pipeline Insights, 2015
• Fallopian Tube Cancer-Pipeline Insights, 2015
• Ocular Inflammation-Pipeline Insights, 2015
• Familial Adenomatous Polyposis Coli-Pipeline
  Insights, 2015
• Ocular Pain-Pipeline Insights, 2015
• Oligodendroglioma-Pipeline Insights, 2015
• Familial Chylomicronemia (Type I
  Hyperlipoproteinemia)-Pipeline Insights, 2015

9
Follow Us
https//www.facebook.com/aarkstoredotcom
https//twitter.com/aarkstore
https//plus.google.com/Aarkstoredotcom/posts
https//www.linkedin.com/company/aarkstore-enterpr
ise
10
Contact Us
Office Address Office No. - 809, 8th
Floor,B-Wing, Mahaavir Icon, Plot No.- 89 90,
Sector-15,CBD-Belapur, Navi Mumbai
400614, Maharashtra, India. Mail us at
contact_at_aarkstore.com 24/7 Online Support 91
9987295242 General Inquiries 91 - 22 2756 4953